Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas

Inclusion Criteria:

Histologically confirmed relapsed or refractory solid tumor or lymphoma including:

Neuroblastoma
Osteosarcoma
Ewing's sarcoma
Rhabdomyosarcoma
Wilms tumor
CNS tumors
Histological verification not required for brainstem tumors
No acute leukemia
Not eligible for higher priority COG phase I/II study
Performance status - Karnofsky 50-100% (over age 10)
Performance status - Lansky 50-100% (age 10 and under)
At least 2 months
Absolute neutrophil count at least 1,000/mm^3
Platelet count at least 75,000/mm^3 (transfusion independent)
Hemoglobin at least 8.0 g/dL (transfusion allowed)
No granulocytopenia, anemia, and/or thrombocytopenia due to bone marrow involvement
Bilirubin no greater than 1.5 times normal
SGPT no greater than 5 times normal
Albumin at least 2 g/dL
Creatinine no greater than 1.5 times normal
Creatinine clearance or radioisotope glomerular filtration rate at least lower limit of normal
Shortening fraction at least 27% by echocardiogram
Ejection fraction at least 50% by MUGA
Stable neurologic deficits within the past 2 weeks for patients with CNS tumors
CNS toxicity less than grade 2
No active graft-versus-host disease
No active uncontrolled infection or other serious medical condition
No uncontrolled diabetes mellitus
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
At least 7 days since prior biologic therapy and recovered
Prior bone marrow or stem cell transplantation allowed
At least 6 months since prior allogeneic stem cell transplantation
At least 1 week since prior growth factors
No concurrent immunomodulating agents
At least 2 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas) and recovered
No other concurrent chemotherapy
Concurrent dexamethasone for CNS tumors allowed if on stable dose for at least 2 weeks prior to study
Concurrent corticosteroids allowed only for increased intracranial pressure in patients with CNS tumors
At least 2 weeks since prior local (small port) palliative radiotherapy
At least 6 months since prior radiotherapy to 50% or more of the pelvis
At least 6 months since prior craniospinal radiotherapy
At least 6 weeks since other prior substantial bone marrow radiotherapy
Recovered from prior radiotherapy
No concurrent radiotherapy except localized palliative radiotherapy
No concurrent anticonvulsants